Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Mayo Clinic

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.
The E3 ubiquitin ligase Itch and Yap1 have antagonistic roles in the regulation of ASPP2 protein stability
Gao, Kun , An, Jian , Jin, Xiaofeng , Peng, Jingtao, Tang, Yan , Yu, Long , Zhang, Pingzhao , Zhang, Yuanyuan , Ma, Jian , Wang, Chenji

Mayo Clinic

FEBS Letters | November 30, 2014 | Volume: 589 | Issue: 1 | Pages: 94-101

10.1016/j.febslet.2014.11.030 | PMID 25436413 Get It

ASPP2 is an important tumor suppressor protein promoting p53‐dependent and‐independent apoptosis. However, it has been unclear how ASPP2 protein is regulated. Here, we identified Itch as the E3 ubiquitin ligase for ASPP2. Itch interacts with ASPP2 and mediates its degradation and ubiquitination in vivo. The PPXY motif of ASPP2 interacts with the WW domains of Itch. Yap1 competes with Itch for binding to ASPP2, and prevents Itch‐mediated degradation and ubiquitination of ASPP2. Together, these observations reveal that Itch and Yap1 have antagonistic roles in the regulation of ASPP2 protein stability through competing post‐translational regulatory mechanism of ASPP2.
Experimental Sleep Restriction Causes Endothelial Dysfunction in Healthy Humans
Calvin, Andrew D. , Covassin, Naima , Kremers, Walter K. , Adachi, Taro, Macedo, Paula , Bukartyk, Jan , Davison, Diane E., Levine, James A. , Singh, Prachi , Wang, Shihan , Albuquerque, Felipe N. , Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Kremers, Walter K

Mayo Clinic

Journal of the American Heart Association | November 25, 2014 | Volume: 3 | Issue: 6 | Pages: No page available

10.1161/jaha.114.001143 | PMID 25424573 Get It

Background Epidemiologic evidence suggests a link between short sleep duration and cardiovascular risk, although the nature of any relationship and mechanisms remain unclear. Short sleep duration has also been linked to an increase in cardiovascular events. Endothelial dysfunction has itself been implicated as a mediator of heightened cardiovascular risk. We sought to determine the effect of 8 days/8 nights of partial sleep restriction on endothelial function in healthy humans. Methods and Results Sixteen healthy volunteers underwent a randomized study of usual sleep versus sleep restriction of two‐thirds normal sleep time for 8 days/8 nights in a hospital‐based clinical research unit. The main outcome was endothelial function measured by flow‐mediated brachial artery vasodilatation ( FMD ). Those randomized to sleep restriction slept 5.1 hours/night during the experimental period compared with 6.9 hours/night in the control group. Sleep restriction was associated with significant impairment in FMD (8.6±4.6% during the initial pre‐randomization acclimation phase versus 5.2±3.4% during the randomized experimental phase, P =0.01) whereas no change was seen in the control group (5.0±3.0 during the acclimation phase versus 6.73±2.9% during the experimental phase, P =0.10) for a between‐groups difference of −4.40% (95% CI −7.00 to −1.81%, P =0.003). No change was seen in non‐flow mediated vasodilatation ( NFMD ) in either group. Conclusion In healthy individuals, moderate sleep restriction causes endothelial dysfunction. Clinical Trial Registration URL : ClinicalTrials.gov. Unique identifier: NCT 01334788.
Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials
Mulla, Sohail, Buckley, D. Norman , Moulin, Dwight E. , Couban, Rachel , Izhar, Zain, Agarwal, Arnav , Panju, Akbar, Wang, Li , Kallyth, Sun Makosso, Turan, Alparslan , Montori, Víctor M. , Thabane, Lehana , Busse, Jason W. , Agarwal, Arnav , Sessler, Daniel I. , Guyatt, Gordon , Montori, Victor M , Thabane, Lehana

Mayo Clinic

BMJ Open | November 21, 2014 | Volume: 4 | Issue: 11 | Pages: e006112

10.1136/bmjopen-2014-006112 | PMID 25412864 Get It

Introduction Chronic neuropathic pain is associated with reduced health-related quality of life and substantial socioeconomic costs. Current research addressing management of chronic neuropathic pain is limited. No review has evaluated all interventional studies for chronic neuropathic pain, which limits attempts to make inferences regarding the relative effectiveness of treatments. Methods and analysis We will conduct a systematic review of all randomised controlled trials evaluating therapies for chronic neuropathic pain. We will identify eligible trials, in any language, by a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, DARE, PsychINFO and the Cochrane Central Registry of Controlled Trials. Eligible trials will be: (1) enrol patients presenting with chronic neuropathic pain, and (2) randomise patients to alternative interventions (pharmacological or non-pharmacological) or an intervention and a control arm. Pairs of reviewers will, independently and in duplicate, screen titles and abstracts of identified citations, review the full texts of potentially eligible trials and extract information from eligible trials. We will use a modified Cochrane instrument to evaluate risk of bias of eligible studies, recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) to inform the outcomes we will collect, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate our confidence in treatment effects. When possible, we will conduct: (1) in direct comparisons, a random-effects meta-analysis to establish the effect of reported therapies on patient-important outcomes; and (2) a multiple treatment comparison meta-analysis within a Bayesian framework to assess the relative effects of treatments. We will define a priori hypotheses to explain heterogeneity between studies, and conduct meta-regression and subgroup analyses consistent with the current best practices. Ethics and Dissemination We do not require ethics approval for our proposed review. We will disseminate our findings through peer-reviewed publications and conference presentations. Trial registration number PROSPERO (CRD42014009212).
α 2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction
Peng, Yin, Che, Pulin , Gannon, Mary , Liu, Yin , Li, Ling , Bu, Guojun , Groen, Thomas van , Jiao, Kai , Wang, Qin , Chen, Yunjia , Peng, Yin, Bu, Guojun

Mayo Clinic

Proceedings of the National Academy of Sciences | November 20, 2014 | Volume: 111 | Issue: 48 | Pages: 17296-17301

10.1073/pnas.1409513111 | PMID 25404298 Get It

Significance Endocytic sorting of amyloid precursor protein (APP) governed by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and the generation of amyloid β (Aβ) peptides, the key pathogenic factor of Alzheimer's disease (AD). This study provides the first evidence to our knowledge that a G protein-coupled receptor, namely, the α 2A adrenergic receptor, modulates APP endocytic sorting and promotes Aβ generation through disrupting APP interaction with a Vps10 family protein, sorting-related receptor with A repeat. Significantly, blockade of α 2A AR by a clinical antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting repurposing clinical α 2 AR antagonists as a new direction for AD treatment.
Chemoreflex physiology and implications for sleep apnoea: insights from studies in humans
Mansukhani, Meghna P. , Wang, Shihan , Somers, Virend K. , Mansukhani, Meghna P

Mayo Clinic

Experimental Physiology | November 15, 2014 | Volume: 100 | Issue: 2 | Pages: 130-135

10.1113/expphysiol.2014.082826 | PMID 25398715 Get It

New Findings What is the topic of this review? This review summarizes chemoreflex physiology in health and disease, with specific focus on chemoreflex‐mediated pathophysiology in obstructive and central sleep apnoea. What advances does it highlight? Chemoreflex mechanisms are thought to contribute significantly to the pathophysiology and adverse outcomes seen in sleep apnoea. Clinical implications of altered chemoreflex function in sleep apnoea from recent studies in humans, including cardiac arrhythmias, coronary artery disease, systolic/diastolic heart failure and sudden cardiac death are highlighted. Activation of the chemoreflex in response to hypoxaemia results in an increase in sympathetic neural outflow. This process is predominantly mediated by the peripheral chemoreceptors in the carotid bodies and is potentiated by the absence of the sympatho‐inhibitory influence of ventilation during apnoea, as is seen in patients with sleep apnoea. In these patients, repetitive nocturnal hypoxaemia and apnoea elicit sympathetic activation, which may persist into wakefulness and is thought to contribute to the development of systemic hypertension and cardiac and vascular dysfunction. Chemoreflex activation could possibly lead to adverse cardiovascular outcomes, such as nocturnal myocardial infarction, systolic and/or diastolic heart failure, cardiac arrhythmias and sudden death in patients with sleep apnoea. This review summarizes chemoreflex physiology in health and disease, with specific focus on chemoreflex‐mediated pathophysiology in obstructive and central sleep apnoea. Measurement of the chemoreflex response may serve as a potential avenue for individualized screening for cardiovascular disease. Whether modulation of this response in sleep apnoea may aid in the prevention and treatment of adverse cardiovascular consequences will require further study.
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk
Painter, Jodie N. , Batra, Jyotsna , Cheng, Timothy, Lose, Felicity , Dennis, Joe, Michailidou, Kyriaki , Ahmed, Shahana, Ferguson, Kaltin , Healey, Catherine S., Kaufmann, S., Hillman, Kristine M. , Walpole, Carina , Moya, Leire , Pollock, Pamela M. , Jones, Angela, Howarth, Kimberley, Martin, L. J., Gorman, Maggie, Hodgson, Shirley, (NSECG), National Study of Endometrial Cancer Genetics Group, Polanco, Ma. Magdalena Echeverry De, Sans, Monica, Carracedo, Angel, Castellvi-Bel, Sergi, Rojas-Martinez, Augusto, Santos, Erika, Teixeira, Manuel R., Carvajal-Carmona, Luis, Shu, Xiao-Ou, Long, Jirong, Zheng, Wei, Xiang, Yong-Bing, (ANECS), The Australian National Endometrial Cancer Study Group, Montgomery, Grant W., Webb, Penelope M., Scott, Rodney J., McEvoy, Mark, Attia, John, Holliday, Elizabeth, Martin, Nicholas G., Nyholt, Dale R., Henders, Anjali K., Fasching, Peter A., Hein, Alexander, Beckmann, Matthias W., Renner, Stefan P., Dörk, Thilo, Hillemanns, Peter, Dürst, Matthias, Runnebaum, Ingo, Lambrechts, Diether, Coenegrachts, Lieve, Schrauwen, Stefanie, Amant, Frederic, Winterhoff, Boris, Dowdy, Sean C., Goode, Ellen L., Teoman, Attila, Salvesen, Helga B., Trovik, Jone, Njolstad, Tormund S., Werner, Henrica M.J., Ashton, Katie, Proietto, Tony, Otton, Geoffrey, Tzortzatos, Gerasimos, Mints, Miriam, Tham, Emma, RENDOCAS, Hall, Per, Czene, Kamila, Liu, Jianjun, Li, Jingmei, Hopper, John L., Southey, Melissa C., (AOCS), Australian Ovarian Cancer Study, Ekici, Arif B., Ruebner, Matthias, Johnson, Nicola, Peto, Julian, Burwinkel, Barbara, Marme, Frederik, Brenner, Hermann, Dieffenbach, Aida K., Meindl, Alfons, Brauch, Hiltrud, Network, The GENICA, Lindblom, Annika, Depreeuw, Jeroen, Moisse, Matthieu, Chang-Claude, Jenny, Rudolph, Anja, Couch, Fergus J., Olson, Janet E., Giles, Graham G., Bruinsma, Fiona, Cunningham, Julie M., Fridley, Brooke L., Børresen-Dale, Anne-Lise, Kristensen, Vessela N., Cox, Angela, Swerdlow, Anthony J., Orr, Nicholas, Bolla, Manjeet K., Wang, Qin, Weber, Rachel Palmieri, Chen, Zhihua, Shah, Mitul, French, Juliet D., Pharoah, Paul D.P., Dunning, Alison M., Tomlinson, Ian, Easton, Douglas F., Edwards, Stacey L., Thompson, Deborah J., Spurdle, Amanda B., Webb, Penelope M. , Chenevix‐Trench, Georgia , Spurdle, Amanda B. , Brauch, Hiltrud , Dörk, Thilo , Cox, Angela , Giles, Graham G. , Southey, Melissa C. , Zheng, Wei , Shu, Xiao‐Ou , Long, Jirong , Dunning, Alison M. , Lindblom, Annika , Ekici, Arif B. , Czene, Kamila , Liu, Jianjun , Carracedo, Ángel , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Martin, Nicholas G. , Montgomery, Grant W. , Brenner, Hermann , Swerdlow, Anthony J. , Orr, Nick , Li, Jingmei , Bowtell, David D.L. , Weber, Rachel Palmieri , Nyholt, Dale R. , Rabstein, Sylvia , Lotz, Anne , Moisse, Matthieu , Teixeira, Manuel R. , French, Juliet D. , McEvoy, Mark , Njølstad, Tormund S. , Tham, Emma , Renner, Stefan P. , Henders, Anjali K. , Lambrechts, Diether , Rogatto, Sílvia Regina , Nicklin, James , Scott, Rodney J. , O’Mara, Tracy A. , Cheng, Timothy, Dennis, Joe, Tyrer, Jonathan P. , Ahmed, Shahana, Jones, Angela, Howarth, Kimberley, Gorman, Maggie, (NSECG), National Study of Endometrial Cancer Genetics Group, Polanco, Ma. Magdalena Echeverry De, Sans, Monica, Carracedo, Angel, Castellvi-Bel, Sergi, Rojas-Martinez, Augusto, Santos, Erika, Teixeira, Manuel R., Carvajal-Carmona, Luis, Shu, Xiao-Ou, Long, Jirong, Zheng, Wei, Xiang, Yong-Bing, (ANECS), The Australian National Endometrial Cancer Study Group, Montgomery, Grant W., Webb, Penelope M., Scott, Rodney J., McEvoy, Mark, Attia, John, Holliday, Elizabeth, Martin, Nicholas G., Nyholt, Dale R., Henders, Anjali K., Fasching, Peter A., Hein, Alexander, Beckmann, Matthias W., Renner, Stefan P., Dörk, Thilo, Hillemanns, Peter, Dürst, Matthias, Runnebaum, Ingo, Lambrechts, Diether, Coenegrachts, Lieve, Schrauwen, Stefanie, Amant, Frederic, Winterhoff, Boris, Dowdy, Sean C., Goode, Ellen L., Teoman, Attila, Salvesen, Helga B., Trovik, Jone, Njolstad, Tormund S., Werner, Henrica M.J., Ashton, Katie, Proietto, Tony, Otton, Geoffrey, Tzortzatos, Gerasimos, Mints, Miriam, Tham, Emma, RENDOCAS, Hall, Per, Czene, Kamila, Liu, Jianjun, Li, Jingmei, Hopper, John L., Southey, Melissa C., (AOCS), Australian Ovarian Cancer Study, Ekici, Arif B., Ruebner, Matthias, Johnson, Nicola, Peto, Julian, Burwinkel, Barbara, Marme, Frederik, Brenner, Hermann, Dieffenbach, Aida K., Meindl, Alfons, Brauch, Hiltrud, Network, The GENICA, Lindblom, Annika, Depreeuw, Jeroen, Moisse, Matthieu, Chang-Claude, Jenny, Rudolph, Anja, Couch, Fergus J., Olson, Janet E., Giles, Graham G., Bruinsma, Fiona, Cunningham, Julie M., Fridley, Brooke L., Børresen-Dale, Anne-Lise, Kristensen, Vessela N., Cox, Angela, Swerdlow, Anthony J., Orr, Nicholas, Bolla, Manjeet K., Wang, Qin, Weber, Rachel Palmieri, Chen, Zhihua, Shah, Mitul, French, Juliet D., Pharoah, Paul D.P., Dunning, Alison M., Tomlinson, Ian, Easton, Douglas F., Edwards, Stacey L., Thompson, Deborah J., Spurdle, Amanda B., Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Spurdle, Amanda B , Teixeira, Manuel R , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , Southey, Melissa C , Martin, Nicholas G , Rogatto, S R , Shu, Xiao-Ou , Dunning, Alison M , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Li, Jingmei , Ekici, Arif B , Moisse, Matthieu , Michailidou, Kyriaki , Chenevix-Trench, Georgia , Zheng, Wei , Czene, Kamila , Bowtell, David D , Batra, Jyotsna , Brauch, Hiltrud , Lindblom, Annika , Orr, Nick , Liu, Jing

Mayo Clinic

Human Molecular Genetics | November 6, 2014 | Volume: 24 | Issue: 5 | Pages: 1478-1492

10.1093/hmg/ddu552 | PMID 25378557 Get It

The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data
Tang, Xiaojia , Baheti, Saurabh , Thompson, Kevin J. , Wills, Quin F., Niu, Nifang, Holcomb, Ilona N., Boutet, Stéphane C., Ramakrishnan, Ramesh, Kachergus, Jennifer M., Kocher, Jean‐Pierre , Weinshilboum, Richard M. , Wang, Liewei , Thompson, E Aubrey, Kalari, Krishna R. , Shameer, Khader, Wills, Quin, Shameer, Khader , Weinshilboum, Richard M. , Thompson, Kevin J , Kalari, Krishna R , Tang, Xiaojia

Mayo Clinic

Nucleic Acids Research | October 29, 2014 | Volume: 42 | Issue: 22 | Pages: e172-e172

10.1093/nar/gku1005 | PMID 25352556 Get It

Abstract Rapid development of next generation sequencing technology has enabled the identification of genomic alterations from short sequencing reads. There are a number of software pipelines available for calling single nucleotide variants from genomic DNA but, no comprehensive pipelines to identify, annotate and prioritize expressed SNVs (eSNVs) from non-directional paired-end RNA-Seq data. We have developed the eSNV-Detect, a novel computational system, which utilizes data from multiple aligners to call, even at low read depths, and rank variants from RNA-Seq. Multi-platform comparisons with the eSNV-Detect variant candidates were performed. The method was first applied to RNA-Seq from a lymphoblastoid cell-line, achieving 99.7% precision and 91.0% sensitivity in the expressed SNPs for the matching HumanOmni2.5 BeadChip data. Comparison of RNA-Seq eSNV candidates from 25 ER+ breast tumors from The Cancer Genome Atlas (TCGA) project with whole exome coding data showed 90.6–96.8% precision and 91.6–95.7% sensitivity. Contrasting single-cell mRNA-Seq variants with matching traditional multicellular RNA-Seq data for the MD-MB231 breast cancer cell-line delineated variant heterogeneity among the single-cells. Further, Sanger sequencing validation was performed for an ER+ breast tumor with paired normal adjacent tissue validating 29 out of 31 candidate eSNVs. The source code and user manuals of the eSNV-Detect pipeline for Sun Grid Engine and virtual machine are available at http://bioinformaticstools.mayo.edu/research/esnv-detect/.
Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group
Wang, Μolin , Fetting, John H., Cella, David , Martino, Silvana, Sparano, Joseph A. , Solin, Lawrence J., Wood, William C., Robert, Nicholas J. , Wang, Molin, Wagner, Lynne I. , Ingle, James N. , Tevaarwerk, Amyé , Zhao, Fengmin , Sparano, Joseph A

Mayo Clinic

Journal of Clinical Oncology | October 28, 2014 | Volume: 32 | Issue: 35 | Pages: 3948-3958

10.1200/jco.2014.55.6993 | PMID 25349302 Get It

PurposeThe effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS.Patients and MethodsPremenopausal women with axillary node-negative, hormone receptor–positive breast cancer tumors measuring ≤ 3 cm were randomly assigned to tamoxifen alone versus tamoxifen plus OFS; adjuvant chemotherapy was not permitted. Primary end points were disease-free survival (DFS) and overall survival (OS). Secondary end points included toxicity and patient-reported outcomes. Patient-reported outcome data included health-related quality of life, menopausal symptoms, and sexual function. These were evaluated at baseline, 6 months, 12 months, and then annually for up to 5 years after registration.ResultsIn all, 345 premenopausal women were enrolled: 171 on tamoxifen alone and 174 on tamoxifen plus OFS. With a median follow-up of 9.9 years, there was no significant difference between arms for DFS (5-year rate: 87.9% v 89.7%; log-rank P = .62) or OS (5-year rate: 95.2% v 97.6%; log-rank P = .67). Grade 3 or higher toxicity was more common in the tamoxifen plus OFS arm (22.4% v 12.3%; P = .004). Patients treated with tamoxifen plus OFS had more menopausal symptoms, lower sexual activity, and inferior health-related quality of life at 3-year follow-up (P < .01 for all). Differences diminished with further follow-up.ConclusionWhen added to tamoxifen, OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self-reported health-related quality of life. Because of early closure, this study is underpowered for drawing conclusions about the impact on survival when adding OFS to tamoxifen.